Denali Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: DNLI · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure, 8-k
Related Tickers: DNLI
TL;DR
DENALI FILED AN 8-K FOR A REG FD DISCLOSURE - BIG NEWS LIKELY DROPPING.
AI Summary
On October 10, 2024, Denali Therapeutics Inc. filed an 8-K to disclose a material event. The filing indicates a Regulation FD Disclosure, suggesting important information was shared with the public that could affect the company's stock price. Specific details of the disclosure are not provided in this excerpt, but the filing type implies a significant announcement.
Why It Matters
This filing signals that Denali Therapeutics has made a public disclosure of material information, which could impact investor decisions and the company's stock valuation.
Risk Assessment
Risk Level: medium — An 8-K filing for a Regulation FD disclosure often precedes significant news that can cause stock price volatility.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- October 10, 2024 (date) — Date of Report
- Regulation FD Disclosure (disclosure) — Item Information
FAQ
What specific information was disclosed under Regulation FD?
The provided excerpt does not specify the exact details of the Regulation FD disclosure, only that it was filed on October 10, 2024.
What is the primary purpose of this 8-K filing?
The primary purpose is to report a Regulation FD Disclosure, indicating the public dissemination of material information.
When was this 8-K filing submitted?
The filing was submitted on October 10, 2024.
What is Denali Therapeutics Inc.'s principal executive office address?
The principal executive offices are located at 161 Oyster Point Blvd., South San Francisco, California 94080.
What is Denali Therapeutics Inc.'s IRS Employer Identification Number?
Denali Therapeutics Inc.'s IRS Employer Identification Number is 46-3872213.
Filing Stats: 610 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-10-10 16:02:20
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI NASDAQ Global Select Mar
Filing Documents
- dnli-20241010.htm (8-K) — 29KB
- 0001714899-24-000205.txt ( ) — 149KB
- dnli-20241010.xsd (EX-101.SCH) — 2KB
- dnli-20241010_lab.xml (EX-101.LAB) — 21KB
- dnli-20241010_pre.xml (EX-101.PRE) — 12KB
- dnli-20241010_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Denali Therapeutics Inc. ("Denali") was informed by its strategic partner Sanofi that the K2 Phase 2 study evaluating the safety and efficacy of oditrasertib (SAR443820/DNL788) on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued based on not meeting the primary and key secondary endpoints. The information furnished in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Forward-Looking Statements
Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those relating to Denali's and Sanofi's plans regarding oditrasertib and the K2 Phase 2 study in multiple sclerosis. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Denali may be found in Denali's Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (the "SEC") on February 28, 2024, and August 1, 2024, respectively, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali's expectations, except as required by law. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: October 10, 2024 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer